抽象
Data from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
具有IPF和保存的强迫生命能力(FVC)的受试者被随机化以接受Nintedanib或安慰剂12周,然后是开放标记的尼丁胺40周。临床血管测定法在基线和周4,8,12,16,20,24,36和52进行。被要求每周至少一次,理想地每天至少一次进行家庭肺活量测量。使用Pearson相关系数评估家庭和诊所测量的FVC与FVC变化率之间的相关性。
总共治疗了346个受试者。平均遵守每周家庭肺活量计量随着时间的推移而降低,但每4周的时间仍然保持在75%以上。超过52周,平均依从性为86%。当由家庭而不是临床肺活量测量时,FVC中基线变化的变化更大。在所有时间点(r = 0.72至0.84)之间在家庭和临床测量的FVC之间观察到强相关性,但FVC的临床测量率之间的相关性和临床测量的变化率之间的相关性弱(r = 0.26,用于下降率FVC超过52周)。
家庭肺活量学是IPF患者肺功能的可行性和有效的肺功能测量,但使用家庭肺活量测定法获得的FVC下降率与基于临床肺活动量的患者的估计差异。
脚注
此手稿最近被接受了出版物欧洲呼吸杂志. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of theerj.线上。请打开或下载PDF以查看本文。
利益冲突:Murray博士从Astrazeneca报告个人费用,来自Thermo Fisher的个人费用,Boehringer Ingelheim的个人费用,来自GSK的个人费用,诺华的个人费用,在提交的工作之外。
Conflict of interest: Dr. Noth reports personal fees from Boehringer Ingelheim, personal fees from Genentech, personal fees from ImmuneWorks, outside the submitted work;.
利益冲突:Cottin博士从Boehringer Ingelheim,拜耳/ MSD的个人费用,诺特里斯,个人费用和非财政支助的个人费用报告了个人费用和非财政支持从Roche,赛道的个人费用,ProMeDior的个人费用,Celgene的个人费用,来自加拉帕戈斯的个人费用,Galecto的个人费用,在提交的工作之外;
Conflict of interest: Dr. Chaudhuri reports grants from Roche, personal fees from Roche, other from Roche, grants from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, other from Boehringer Ingelheim, outside the submitted work;.
利益冲突:Corte博士报告罗伯林·宾列尼姆的赠款和个人费用来自罗氏的赠款和个人费用,来自拜耳的Gilead补助金,来自二期的,来自Astazeneca的个人费用,赠送和个人费用,来自BMS的个人费用,个人费用ProMeDior,来自Ad Alta的个人费用,从NULL开始,在进行该研究期间;
利益冲突:Johannson博士报告个人费用和其他来自霍夫曼拉罗奇有限公司的个人费用和其他来自霍夫曼拉罗什有限公司的个人费用,个人费用和其他来自刀片治疗方法的个人费用,个人费用和其他来自胸部基金会的赠款,来自大学的补助金卡尔加里医学院,卡尔加里肺纤维化协会的补助,来自UCB Biopharma Sprl的补助,来自三个湖基金会,在提交的工作之外;
Conflict of interest: Dr. Wijsenbeek reports grants and personal fees from Boehringer Ingelheim and Hoffman La Roche , personal fees from Galapagos, outside the submitted work. This article was based on discussions held at a meeting supported by Boehringer Ingelheim in June 2017.
利益冲突:Jouneau博士报告了Actelion的个人费用,Astb的个人费用,Astrazeneca的个人费用,来自Bristol-Myers Squibb的个人费用,来自Boehringer Ingelheim的个人费用,来自Chiesi的个人费用,Galecto的个人费用,个人费用Gilead,来自LVL的个人费用的个人费用,Mundipharma的个人费用,诺维利斯的个人费用,辉瑞的个人费用,罗氏的个人费用,罗氏的个人费用,萨尔拉州的个人费用,萨瓦拉 - Serendex的个人费用,在提交的工作之外。
利益冲突:作者(Andy Michael)是Boehringer Ingelheim的承包商。
利益冲突:作者(Manuel Quaresma)是Boehringer Ingelheim International GmbH的员工。
利益冲突:作者(Klaus Rohr)是Boehringer Ingelheim International GmbH的员工。
Conflict of interest: Dr. Russell reports grants and personal fees from Boehringer Ingelheim , grants from Imperial Health Charity, grants from Pulmonary Fibrosis Trust UK, personal fees from Irish Lung Fibrosis Association, grants from Action for Pulmonary Fibrosis, personal fees from Hoffman La Roche, outside the submitted work;.
利益冲突:作者(Susanne Stowasser)是Boehringer Ingelheim International GmbH的员工。
Conflict of interest: Dr. Maher reports personal fees from Apellis, personal fees from Boehringer Ingelheim, grants and personal fees from UCB, personal fees from Roche, personal fees from Bayer, personal fees from Biogen Idec, personal fees from Apellis, personal fees from Galapagos, personal fees from Indalo, personal fees from Galecto, personal fees from Blade, personal fees from Bristol-Myers Squibb, grants and personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Respivent, personal fees from Trevi, outside the submitted work;.
这是一个只有PDF的文章。请单击上面的PDF链接以阅读它。
- 收到5月1日,2020年。
- Accepted2020年12月9日。
- 复制right ©ERS 2021
This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.